BACKGROUND Metformin-associated lactic acidosis (MALA) is a relatively rare adverse effect of metformin therapy. It usually occurs in patients with metformin overdose or in those with underlying acute and/or chronic conditions resulting in impaired lactate metabolism. Among these, patients with acute kidney injury, heart failure, sepsis, and cirrhosis are the most vulnerable to MALA, even in the setting of appropriate therapy. The most common symptoms of MALA include nausea, vomiting, diarrhea, encephalopathy, hypothermia, respiratory failure, and hypotension. Blindness is a dramatic symptom that has been rarely reported with MALA. CASE REPORT We report a case of 78-year-old woman with history of type 2 diabetes mellitus with nephropathy for which she was treated with metformin and insulin. She developed nausea, non-bloody emesis, and watery diarrhea, which led to dehydration, anion gap metabolic acidosis due to hyperlactatemia, and acute kidney injury (AKI). She was hospitalized for i.v. hydration and further management when she suddenly developed blindness. The diagnostic work-up ruled out central causes and her symptoms resolved briefly after continuous renal replacement therapy (CRRT) was initiated, confirming the diagnosis of MALA. CONCLUSIONS By reporting this case, we wish to increase awareness about MALA symptoms, its diagnosis, and the importance of early recognition and initiation of treatment among clinicians involved in the care of patients with chronic kidney disease (CKD) who take metformin for diabetes mellitus. Although rare, this metformin adverse effect can present dramatically and can be distressing for both patient and treating team.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026230PMC
http://dx.doi.org/10.12659/AJCR.935730DOI Listing

Publication Analysis

Top Keywords

metformin-associated lactic
8
lactic acidosis
8
acidosis mala
8
acute kidney
8
kidney injury
8
diabetes mellitus
8
mala
7
metformin
5
transient complete
4
complete blindness
4

Similar Publications

Article Synopsis
  • The study focused on identifying situations that lead to metformin-associated lactic acidosis (MALA) in ICU patients and evaluating its preventability.
  • A total of 198 MALA cases were assessed, with 19.2% resulting in death; the majority of patients had acute events like dehydration or severe infections that contributed to the condition.
  • The findings indicated that MALA is often preventable, highlighting the need for better physician and patient education regarding metformin use during high-risk medical situations.
View Article and Find Full Text PDF

Introduction: Metformin is a first line treatment for type II diabetes. Cases of metformin-associated lactic acidosis are regularly reported. A direct causal link between metformin overdose and lactic acidosis is not clearly established.

View Article and Find Full Text PDF

Extracorporeal therapies could be required for treatment of life-threatening severe acute intoxication. We present the case of an 82-year-old patient admitted to our Nephrology Unit because of metformin-associated lactic acidosis (MALA) and acute kidney injury (AKI stage III AKIN criteria). The patient also presented severe intoxication of digoxin and apixaban.

View Article and Find Full Text PDF

Lactic acidosis is a rare metabolic complication that can occur in patients with diabetes mellitus type 2 who use metformin. We discuss a 79-year old woman with metformin-associated lactic acidosis (MALA) and acute kidney injury based on gastroenteritis. Patient reported acute blindness which in literature is described as a rare presentation of a metabolic acidosis (regardless of its underlying cause).

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to analyze trends in the use of antidiabetic medications in patients with chronic kidney disease (CKD) and identify the risk of metformin-associated lactic acidosis (MALA).
  • It involved a review of electronic medical records from 2010 to 2021, focusing on patients over 18 with both CKD and type 2 diabetes who had been on antidiabetic drugs for at least 30 days.
  • Metformin was the most commonly prescribed drug for earlier stages of CKD, but its use declined significantly in advanced stages, while SGLT2 and DPP-4 inhibitors saw increased prescriptions, highlighting varying treatment patterns and low MALA risk in CKD patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!